Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 10/20 | 1.00 |
| ▸ | ROCK1 | Q13464 | 10/20 | 1.00 |
| ▸ | CCR2 | P41597 | 5/20 | 1.00 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.54 |
| ▸ | DRD4 | P21917 | 3/20 | 0.53 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.52 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5639778 | 0.93 | ROCK1 (0.88) | ROCK2ROCK1CCR2 | |
| SCHEMBL5637871 | 0.93 | ROCK1 (0.88) | ROCK2ROCK1CCR2 | |
| SCHEMBL5637873 | 0.93 | ROCK1 (0.88) | ROCK2ROCK1CCR2 | |
| SCHEMBL5639880 | 0.90 | ROCK2 (0.82) | ROCK2ROCK1CCR2DRD4SIGMAR1 | |
| SCHEMBL5639733 | 0.90 | ROCK2 (0.81) | ROCK2ROCK1CCR2DRD4SIGMAR1 | |
| SCHEMBL5640347 | 0.89 | ROCK2 (0.80) | ROCK2ROCK1CCR2DRD4SIGMAR1 | |
| SCHEMBL5640737 | 0.87 | ROCK2 (1.00) | ROCK2ROCK1CCR2 | |
| SCHEMBL5641128 | 0.87 | ROCK2 (0.77) | ROCK2ROCK1CCR2DRD4SIGMAR1 | |
| SCHEMBL5641682 | 0.84 | ROCK2 (0.73) | ROCK2ROCK1CCR2DRD4SIGMAR1 | |
| SCHEMBL5642402 | 0.84 | ROCK2 (0.72) | ROCK2ROCK1CCR2DRD4SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7217722-B2 | Nitrogen-containing compounds having kinase inhibitory activity and drugs containing the same | KIRIN BEER KABUSHIKI KAISHA (JP) | 2007-05-15 | — | — | US | disclosed |
| US-7217722-B2 | Nitrogen-containing compounds having kinase inhibitory activity and drugs containing the same | KIRIN BEER KABUSHIKI KAISHA (JP) | 2007-05-15 | — | — | US | disclosed |
| US-7217722-B2 | Nitrogen-containing compounds having kinase inhibitory activity and drugs containing the same | KIRIN BEER KABUSHIKI KAISHA (JP) | 2007-05-15 | — | — | US | disclosed |
| US-20040102437-A1 | Nitrogen-containing compounds having kinase inhibitory activity and drugs containing the same | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2004-05-27 | — | — | US | disclosed |
| EP-1256574-A1 | NITROGEN-CONTAINING COMPOUNDS HAVING KINASE INHIBITORY ACTIVITY AND DRUGS CONTAINING THE SAME | KIRIN BEER KABUSHIKI KAISHA (JP) | 2002-11-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040102437-A1 | Nitrogen-containing compounds having kinase inhibitory activity and drugs containing the same | TNK2, ROCK1, ROCK2 | ROCK2 3/4885ROCK1 2/4885CCR2 3344/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.